GRAIL to Present New Galleri® Data From More Than 32,000 Participants Across the PATHFINDER 2, SYMPLIFY and REFLECTION Studies at ESMO Congress 2025 and EDCC

Core Insights - GRAIL, Inc. will present new data on the Galleri multi-cancer early detection test at the ESMO Congress 2025, highlighting its performance and safety from the PATHFINDER 2 study [1] - The results will also be submitted to the FDA as part of the Galleri Premarket Approval Application [1] - Additional updated results from the SYMPLIFY and REFLECTION studies will be presented at the Early Detection of Cancer Conference, showcasing Galleri's performance in symptomatic and veteran populations [1] Company Highlights - GRAIL, Inc. is focused on early cancer detection, aiming to identify cancer when it is still curable [1] - The company is leveraging data from its registrational PATHFINDER 2 study to support its claims regarding the Galleri test [1] - The upcoming presentations at major conferences indicate GRAIL's commitment to advancing its research and regulatory approval processes [1]